Aligos Therapeutics (ALGS) Change in Accured Expenses (2019 - 2026)

Aligos Therapeutics (ALGS) has 8 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 67.74% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 188.47% YoY) and the FY2025 annual result came in at -$2.0 million, down 46.33% from the prior year.
• Change in Accured Expenses retreated to -$1.5 million in Q1 2026, from -$79000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q4 2023 to a low of -$6.4 million in Q2 2022.
• A 5-year average of -$826470.6 and a median of -$79000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 412.27% — and 2025, when it surged 6322.73%.
• Tracing ALGS's Change in Accured Expenses over 5 years: stood at $2.4 million in 2022, then jumped by 55.07% to $3.7 million in 2023, then tumbled by 65.08% to $1.3 million in 2024, then sank by 106.11% to -$79000.0 in 2025, then sank by 1845.57% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), -$79000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.